Loading
VOR-001 is an oral medicine from Vortex Therapeutics designed to block the cancer-driving protein MYC directly; it has been tested in animals so far.
VOR-001 is the lead programme of Vortex Therapeutics, described as an orally bioavailable small-molecule MYC inhibitor selected to advance to an investigational new drug application. The company reports nanomolar binding to MYC, tumour regression in a mouse hepatocellular carcinoma model and a predicted half-life of about 80 hours in preclinical models. No clinical trial is registered.
Described by the company as a direct MYC inhibitor that binds a pocket formed when MYC is acetylated, selectively regulating MYC target genes. Connects to MYC.
1.VOR-001 slips into a pocket on MYC.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"VOR-001" OR ABSTRACT:"VOR-001") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about VOR-001, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/